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Abstract
Background: While eating disorder not otherwise specified (EDNOS) is the most common eating disorder (ED)
diagnosis in routine clinical practice, no specific treatment methods for this diagnosis have yet been developed and
studied. Enhanced cognitive behavioral therapy (CBT-E) has been described and put to the test as a transdiagnostic
treatment protocol for all EDs, including EDNOS. Initial research in the UK suggests that CBT-E is more effective for
EDs, especially bulimia nervosa (BN) and EDNOS, than the earlier version of CBT. These positive results of CBT-E
have to be replicated in more detail, preferably by independent researchers in different countries. Being the first
Dutch study into CBT-E, the results from this national multicenter study – on three sites specialized in EDs – will
deliver important information about the effectiveness of CBT-E in several domains of ED pathology, while providing
input for the upcoming update of the Dutch Multidisciplinary Guideline for the Treatment of Eating Disorders.
Methods/design: A multicenter randomized controlled trial will be conducted. One hundred and thirty-two adult
outpatients (aged 18 years and older) with an ED diagnosis and a Body Mass index (BMI) of between 17.5 and 40
will be randomly allocated to the control or the intervention group. Subjects in the control group will receive
Treatment as Usual (standard outpatient treatment provided at the participating sites). Subjects in the intervention
group will receive 20 sessions of CBT-E in 20 weeks. The design is a 2 (group) × 5 (time) repeated measures factorial
design in which neither therapists nor patients will be blinded for treatment allocation. The primary outcome
measure is recovery from the ED. Secondary outcome measures include ED psychopathology, common mental
disorders, anxiety and depressive symptoms, health-related quality of life, health care use and productivity loss.
Self-esteem, perfectionism and interpersonal problems will be examined as putative predictors and mediators of
the effect of treatment. Also, an economic evaluation from a societal perspective will be undertaken. All relevant
effects, direct and indirect costs will be included. Utility scores will measure the effects. Measurements will take
place at pretreatment, 6 weeks, 20 weeks, 40 weeks and 80 weeks.
Discussion: This effectiveness study into CBT-E has the aim of broadening the scope and generalizability of former
studies. If CBT-E appears to be at least as effective as traditional diagnosis-specific treatments for a broad range of
ED patients, training in one protocol would be sufficient for clinicians to treat patients with different kinds of EDs. It
gives the opportunity to offer treatment for a severe mental disorder with fewer resources, thereby increasing the
accessibility of specialized care for patients with an ED.
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Background
Eating disorders (EDs) are severe mental disorders,
which typically begin in adolescence [1–4]. In the fourth
edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) [5] three EDs are recognized: anorexia
nervosa (AN), bulimia nervosa (BN) and a residual diag-
nostic category called eating disorder not otherwise speci-
fied (EDNOS) including binge eating disorder (BED). In
the new edition, DSM-5 [6], BED has been added as a new
official diagnosis [7]. Prior to the official recognition of
BED as a specific DSM-5 ED, several studies into the effi-
cacy of specific BED interventions have been performed
[8], utilizing DSM-IV research criteria. In DSM-5, the
remaining EDs from the DSM-IV EDNOS category have
been redefined into two categories: other specified feeding
or eating disorder (OSFED) and unspecified feeding or
eating disorder (USFED).
These developments have complicated direct compari-
sons between research data on the DSM-IV EDNOS and
the DSM-5 BED, OSFED and USFED categories.
The effectiveness research on EDs has focused on BN
and, more recently, BED. Studies of good quality on
DSM-IV EDNOS (with the exception of BED) and AN
are limited. This paucity of research on ED symptoms
summarized in the DSM-IV EDNOS category is a ser-
ious problem, as EDNOS has been the most common
ED diagnosis (50–77%) in routine clinical practice [9, 10],
and is responsible for severe morbidity, loss of quality of
life and even an annual mortality rate of 3.3 per 1000 per-
son years [11]. General health care utilization among this
group of patients is high [12], and about 62% are referred
to mental health care by their GPs [13].
EDNOS often refers to ED psychopathology that does
not meet the full diagnostic criteria of one of the specific
EDs (i.e., AN or BN). Examples are: (in women) all symp-
toms of AN except amenorrhea, and compensatory behav-
ior by individuals of normal weight after eating small
amounts of food. Although the use of DSM-5 criteria ef-
fectively reduces the frequency of the residual diagnosis
EDNOS (for example, by lowering the threshold for AN
and BN and adding BED as a specified ED), the magnitude
of this reduction varies across studies [14].
The three most prominent guidelines – from the UK
National Institute for Health and Care Excellence in 2004
[15], from the American Psychiatric Association in 2006
[16] and the most recent from the Royal Australian and
New Zealand College of Psychiatrists in 2014 [17] –
recommend cognitive behavioral therapy (CBT) as the
psychological treatment of first choice, specifically for
BN and BED. Specific treatment recommendations for
AN are less forthcoming due to the paucity of positive
outcome data in this area. These recommendations con-
cur with those from the Dutch Multidisciplinary Guideline
for the Treatment of Eating Disorders in 2006 [18].
Fairburn [19] developed a relatively short transdiag-
nostic CBT, CBT-E(nhanced), designed to be suitable for
the full range of ED diagnoses. CBT-E is based upon the
transdiagnostic theory of the maintenance of EDs, in
which it is assumed that most of the mechanisms in-
volved in the persistence of EDs are common to all three
EDs, rather than being specific to each diagnostic group
separately [20]. According to Fairburn and colleagues,
EDs have more similarities than differences, especially
the core psychopathology (over-evaluation of shape and
weight) and expression in attitudes and behavior (dietary
restriction, dietary rules, binges, self-induced vomiting,
etc.). CBT-E, the enhanced version of CBT, uses new
strategies and procedures to address mechanisms that
are central to the maintenance of all EDs, including the
diversity of ED psychopathology that until recently
comprised the DSM-IV EDNOS category. CBT-E is
characterized by increased focus on engagement, greater
emphasis on the modification of concerns about shape
and weight, and the development of skills to deal with
setbacks. Regardless of ED diagnosis, CBT-E is designed
as an individualized and “modular” form of treatment, in
which specific modules may be directed at the particular
maintaining mechanisms operating in the individual
patient’s case.
There are two forms of CBT-E: a focused form (CBT-Ef)
that targets ED psychopathology exclusively (e.g., proce-
dures directed at over-evaluation of shape and weight), and
a more complex broad form (CBT-Eb) that also addresses
additional problems that appear to maintain EDs or
complicate their treatment. Fairburn et al. [21] state that
additional mechanisms such as clinical perfectionism, low
self-esteem and interpersonal problems maintain the
ED psychopathology and thereby obstruct change dur-
ing the treatment with CBT-E. The broad version of
CBT-E was designed to focus on these mechanisms.
For both versions of CBT-E two variants of intensity
have been developed: 20 sessions in 20 weeks for the
patients who are not significantly underweight (Body
Mass Index (BMI) above 17.5), and 40 sessions in
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40 weeks for the patients who are significantly under-
weight (BMI below 17.5).
First studies have found CBT-E to be more efficacious
than other psychological approaches [22–24]. It seems
feasible to treat a broad range of ED patients with CBT-
E, but more evidence is required according to a recent
meta-analysis [25] and the most recent guidelines [17].
The current study will not only evaluate the effective-
ness of CBT-E in terms of the reduction of ED psycho-
pathology and additional comorbid psychopathology and
enhancement of quality of life and health status, but also
the cost-effectiveness of CBT-E relative to regular ED
therapy. Treatment as Usual (TAU) for patients with an
ED varies per ED category. For BN and BED there are
well-described and evaluated CBT protocols [26, 27].
For AN and EDNOS (except BED) evidence-based treat-
ment protocols are lacking and treatments vary greatly.
There are no empirical data about duration, intensity
and costs of regular therapy for EDs in The Netherlands.
However, consulted independent ED experts in the
Netherlands and Belgium have estimated that TAU for
EDs is probably more intensive, long-term and less
effective than CBT-E. Therefore, we expect CBT-E to be
more cost-effective compared to regular treatment.
If CBT-E indeed appears to be at least as effective as
traditional diagnosis-specific treatments for a broad range
of ED patients, this unified transdiagnostic approach for
all EDs would give the opportunity to offer treatment for a
severe mental disorder with fewer resources and, there-
fore, increase the accessibility of an evidence-based
treatment for patients with an ED.
In this study we only use the focused version (CBT-Ef)
for patients with a BMI above 17.5. BMI above 17.5 is
considered by Fairburn as the critical limit for the 20-
session CBT-E variant. Additional measurements on top
of the outcome measures and those for quality of life
and health status involve perfectionism, self-esteem and
interpersonal problems. These are believed to be possible
clinical and research indications for obstruction in change
and progress. Measurements will be taken before, during
and after treatment to explore the predictive and mediat-
ing effects on treatment outcome.
Methods/design
Design
We will execute a multicenter randomized controlled
trial (RCT) with two equal-sized parallel groups at three
specialized ED treatment centers from three regions in
The Netherlands. Participants will be randomized into
two groups (CBT-E versus TAU) stratified by ED center
and type of ED. Measurements will take place at pre-
treatment, 6 weeks, 20 weeks, 40 weeks and 80 weeks,
resulting in a 2 (group) × 5 (time) repeated measures
factorial design. For an overview of the proposed flow of
participants, see Fig. 1. The present study protocol was
written in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
[28]; copies of the SPIRIT Checklist and figure have
been included in Additional files 1 and 2.
Participants
Participants will consist of 132 adult outpatients aged
from 18 years with an ED diagnosis according to DSM-5
and a BMI of between 17.5 and 40. They are recruited at
the participating mental health centers: PsyQ/Parnassia
Psychiatric Institute in The Hague will include 60
patients and PsyQ/Lentis Psychiatric Institute in
Groningen and Rintveld/Altrecht Mental Health Insti-
tute in Zeist both 36 patients.
Inclusion criteria
In order to be eligible to participate in this study, a
participant must meet all of the following criteria:
1. Adult outpatients (from age 18 years) with an ED
diagnosis: AN, BN, BED, OSFED (EDNOS),
according to an adapted version of the SCID-I
(see “Measurement” section) and a BMI of
between17.5 and 40
2. Provision of informed consent
3. Ability to understand Dutch (speaking, listening,
reading)
Exclusion criteria
A potential participant who meets any of the following
criteria will be excluded from participation in this study:
1. Prior treatment that closely resembles CBT-E or
another evidence-based intervention for eating
pathology in the past 2 years
2. A severe Axis-I or -II psychiatric disorder or other
psychosocial circumstances that require priority of
clinical attention and other support and, therefore,
impedes immediate treatment of the ED (e.g.,
psychoses, addiction, suicidality, homelessness)
3. Receiving ongoing psychiatric treatment (except for
antidepressant medication)
4. Intellectual disability
5. Medical instability or pregnancy
6. Not available over the coming 20 weeks
Procedure
Each patient will be recruited at the site at which they
were referred for treatment. All assessors have been
trained in the adjusted SCID-I ED section which will be
used to diagnose Axis-I ED. During intake potential
participants receive information about the research
(treatment conditions, procedure, randomization process,
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confidentiality) from the local assessors. The assessment
staff of each site will decide whether a patient meets the
inclusion or exclusion criteria and whether they are defin-
itely eligible for the study. If this is considered to be the
case, the research assistant (who is located at the logistic
center of the study, PsyQ The Hague) will, for each site,
randomly assign the patient to TAU or CBT-E and send
an email (in attachment) to the assessor. Randomization is
done by making use of a random allocation program,
stratified by center and type of ED. Participation will be
discussed with the patient during a second appointment
with the assessor. If the patient is willing to participate
and has signed the Informed Consent Form, the assessor
will open the email to inform the patient of the condition
they are assigned to. Data will be obtained mainly by
online questionnaires, with exception of the SCID-I ED
section, which will be conducted by telephone, and the
IAT computer task which will be conducted on a stand-
alone computer. Prior to the first treatment session,
patients will be asked to fill out the online questionnaires
and complete the IAT computer task. After 6, 20, 40 and
80 weeks the online questionnaires are obtained. After 20
and 80 weeks the SCID-I will be repeated. After 20 weeks
the IAT task will be repeated (for an overview of the
Fig. 1 Proposed flow of participants. T0 baseline, T1 week 6, T2 end of treatment week 20, T3 follow-up week 40, T4 follow-up week 80. SCID-I
Structured Clinical Interview for DSM Axis-I disorders, EDE-Q The Eating Disorder Examination-Questionnaire, WSQ Web Screening Questionnaire
for common mental disorders, MASQ Mood and Anxiety Questionnaire, EQ-5D EuroQoL five dimensions questionnaire, SF-36 Short Form Health
Survey, TiC-P Trimbos/iMTA Questionnaire for Costs associated with Psychiatric Illness, RSE Rosenberg Self-Esteem Scale, IAT Implicit Association
Test Self-Esteem. F-MPS Frost Multidimensional Perfectionism Scale, IIP-32 Inventory of Interpersonal Problems
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assessments see Fig. 1). Participants who do not complete
the online questionnaires within 1 week will be contacted
by means of personalized emails and/or telephone calls. If
they decide to discontinue study participation, efforts will
be made to retain them in the trial, while respecting their
right to withdraw from participation at any time without
further consequences. Patients will not receive any monet-
ary compensation for their involvement, but treatment
will be delivered free of charge.
Study conditions
CBT-E: a transdiagnostic 20-session version of CBT, CBT-
E(nhanced). In this study we use the focused version for
patients with a BMI above 17.5, designed to be suit-
able for the full range of ED diagnoses. CBT-E is a
treatment for ED psychopathology, rather than for a
specific ED diagnosis. The strategy underpinning
CBT-E is to construct a transdiagnostic formulation
(or set of hypotheses) of the processes that are main-
taining the patient’s psychopathology and to use this
formulation to identify the features that need to be
targeted in treatment. This formulation is constructed
at the beginning of treatment, but will be revised ,if
needed, during therapy. In this way a tailor-made
treatment is created.
Stage 1 (sessions 1–7) is an intensive initial stage, with
appointments twice a week. The therapist and the pa-
tient together set up the formulation of the underlying
maintaining factors, which will be used as a base for the
remainder of the treatment. The aims of this stage are to
engage the patient in treatment.
Stage 2 (sessions 8–9) are weekly appointments. This
stage is a brief stage in which the therapist and patient
take stock, review progress, identify any emerging bar-
riers to change, modify the formulation and plan stage 3.
This stage is important to identify problems with the
therapy, to remove barriers and adjust treatment if
needed. After stage 2 the treatment will become more
personalized.
Stage 3, (sessions 10–17) is the main body of treat-
ment. There are eight weekly appointments. The aim is
to address the main mechanisms that are supposed to
maintain the patient’s ED. How this is done precisely
varies from patient to patient. The therapist can choose
to pay attention to one or more defined maintaining
factors.
Stage 4 (sessions 18–20) is the final stage of treat-
ment and the focus shifts to the future. The appoint-
ments are scheduled at 2-week intervals. There are
two aims: the first one is to ensure that the changes
are maintained (over the subsequent 20 weeks until a
review appointment is held), and the second one is to
minimize the risk of relapse in the long-term.
After 20 weeks there is a review session. The most im-
portant aim in this session is to review what has been
learned and achieved during treatment and what risk fac-
tors are to be taken into account when therapy has ended.
TAU: the usual treatment given at the participating
treatment sites is in general based on CBT, individually
or in a group with elements of existing CBT treatment
protocols [26, 27]. Depending on the site’s treatment
policy, this may vary from low-intensity care (weekly
sessions) to high-intensity care. This high-intensity care
consists of two group sessions a day for 2 days of the
week, sometimes supplemented with individual sessions
due to coexisting psychopathology. Most of the times
more than one discipline (psychologist, dietitian, psych-
iatrist) is involved in applying the treatment. The type of
treatment provided is registered.
Selection and training of therapists
All CBT-E therapists are psychologists/psychiatrists or
registered nurses/social workers (n = 10). All have at
least 2 years of experience as a therapist in the field of
EDs and have been working for at least 2 years accord-
ing to CBT principles. All CBT-E therapists in the
participating centers were trained as a group by
Christopher G. Fairburn and had 20 supervision sessions
through videoconferencing from Zafra Cooper. A Dutch
treatment manual was developed and will be used by all
CBT-E participating therapists. All participating CBT-E
therapists have treated at least three ED patients with
CBT-E under supervision before entering the trial.
All TAU therapists are psychologists/psychiatrists or
registered nurses/social workers who have at least 2 years
of experience as therapists in the field of EDs. TAU did
not include training or supervision of the therapists.
TAU therapists have regularly standard, local collegial
consultation.
The treatment integrity in CBT-E will be evaluated by
recording all CBT-E sessions. Two audiotaped sessions of
every CBT-E patient will be randomly selected (from,
respectively, stages 1/2 and stages 3/4) and the use of spe-
cific therapeutic interventions according to the treatment
manual will be scored on several 7-point Likert scales.
The first 20 audiotapes will be double rated to assess
interrater reliability. Evaluation of the CBT-E sessions will
be executed by psychologists who are familiar with the
treatment protocol (trained through the online training in
CBT-E developed by Fairburn), by ticking on prearranged
checklists whether all due aspects of specific therapy
stages have been handled adequately by the therapist.
Objectives
The primary objective of this study is to assess whether
CBT-E is more optimal in terms of a higher percentage
of recovery from EDs compared to TAU. The secondary
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objectives are to assess whether CBT-E is more effective
in (1) reducing important aspects of ED psychopath-
ology, (2) reducing indications for the presence of
comorbid psychopathological conditions and additionally
comorbid symptoms of anxiety and depression, (3) im-
proving health-related quality of life and (4) effectuating
a better cost-effectiveness, compared to TAU.
Moreover, self-esteem, perfectionism and interpersonal
problems are repeatedly measured during this RCT to
examine their possible predictive and mediating effects
on treatment outcome.
Measurements
Screening and primary treatment outcome
Structured Clinical Interview for DSM Axis-I Disorders
(SCID-I). The SCID-I [29, 30] will be used to assess the
presence of an ED. Only the section about EDs will be
administered. Because the SCID-I only covers AN, BN,
and EDNOS-BED, skip rules were changed or omitted
and parts of the Eating Disorder Examination (EDE)
[31] were added in order to diagnose DSM-5 AN, BN,
BED and OSFED [32]. The interview will be used both
to obtain a DSM-5 diagnosis for inclusion and as a treat-
ment outcome measure at T2 (at the end of treatment,
20 weeks after treatment has started) and T4 (80 weeks
after the start of treatment). Several studies found mod-
erate to excellent interrater agreement for determining
the presence of Axis-I disorders using the original
SCID-I [33] and good test-retest reliability [34, 35].
Secondary study parameters
The Eating Disorder Examination-Questionnaire (EDE-Q)
[36, 37]. This questionnaire is a self-report measure that
was adapted from the interview-based EDE [38] and
measures ED pathology. It consists of 36 items that are
scored on a 7-point scale. The total score is used as an
indicator for the level of ED pathology, with a higher
score denoting more pathology. Good concurrent valid-
ity [39–42], discriminant validity [43] and acceptable
criterion validity [42] have been demonstrated with
adults. Moreover, the EDE-Q has been found to have
good internal consistency and test-retest reliability in
adults [44]. In studies comparing the EDE interview and
EDE-Questionnaire the overall correlation coefficient
ranged from .68 to .76. In general, participants obtain
higher scores in the questionnaire than in the interview
mode of administration [45, 46].
Web Screening Questionnaire for common mental
disorders (WSQ) [47]. This self-report screening instru-
ment will be used to screen for Axis-I disorders. It is a
short screening instrument for depressive disorder, alco-
hol abuse/dependence, generalized anxiety disorder
(GAD), post-traumatic stress disorder (PTSD), social
phobia, panic disorder, agoraphobia, specific phobia, and
obsessive compulsive disorder (OCD). The questionnaire
consists of 15 questions. The sensitivity of the WSQ is
0.72–1.00 and specificity is 0.44–0.77 [47].
Mood and Anxiety Symptom Questionnaire (MASQ)
[48]. The MASQ is a self-report questionnaire to assess
the severity of symptoms of anxiety and depression. It is
based on the tripartite model of anxiety and depression
symptoms, which can be separated into three groups:
global discomfort (anxiety and depression), anhedonia
(specific for depression) and physiological hyperarousal
(specific for anxiety). The questionnaire consists of 90
items, with an answering scale from 1 to 5 (“not” to
“very much”). The scores of the subscales are measured
by summating the scores of the items of the subscales.
The subscales have sufficient discriminant validity, espe-
cially the depression scales [49–51]. The subscales seem
to have sufficient internal consistency [48].
EuroQoL five dimensions questionnaire (EQ-5D) [52].
The EQ-5D aims to measure health-related quality of
life. The EQ-5D is a short questionnaire that consists of
five questions with three answer levels, reflecting “no
problem”, “some problem” and “extreme problem” in
relation to specific dimensions (i.e., mobility, self-care,
usual activity, pain and mood). In addition the EQ-5D
also includes a Visual Analog Scale (VAS) to value the
respondent’s health state, labeled from “best imaginable
health” (100) to “worst imaginable health” (0). The EQ-
5D can be used to assess sociodemographic differences
in health status. Research provides support for the valid-
ity of the EQ-5D as a measure for health status [53].
Short Form Health Survey (SF-36) [54]. We will use
the SF-36 to assess health-related quality of life and
health status. The SF-36 was developed for a wide range
of chronic diseases [54]. It is a multidimensional instru-
ment, with 36 questions to measure eight dimensions:
physical functioning, social functioning, role limitations
(physical and emotional), mental health, vitality, pain,
general health perception and health change. The scores
per dimension will be transformed to a scale from 0 to
100 and a higher score denotes a better health status.
The Dutch translation has good reliability (Cronbach’s
alpha coefficients above .70) and validity [55].
Trimbos/iMTA Questionnaire for Costs associated with
Psychiatric Illness (TiC-P), including the Short Form –
Health and Labour Questionnaire (SF-HLQ) [56]. The
Tic-P is a validated tool commonly applied in economic
evaluations of treatments in mental health care. The
TiC-P is a paper and pencil self-report questionnaire
that consists of two parts. The first part obtains informa-
tion about the volume of health care consumption
(direct costs) and the production losses relative to the
health problem in question (indirect costs), and some
general questions. The second part of the TiC-P, which
measures the indirect costs, is the SF-HLQ. The SF-
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HLQ, an abbreviated version of the HLQ, is a generic
and validated measurement instrument to collect data
on productivity losses related to health problems in indi-
viduals with paid or unpaid work [56]. By multiplying
the volumes by the cost prices, it is possible to calculate
the costs [57].
Putative predictors/mediators
The Rosenberg Self-Esteem Scale (RSE). The RSE is a
widely-used 10-item Likert scale to measure self-esteem.
Items are answered on a 4-point scale – from “strongly
agree” to “strongly disagree” – measuring positive and
negative feelings towards the self [58]. The Dutch version
of the RSE is found to be a one-dimensional scale with
high internal consistency (Cronbach’s alpha of 0.89) and
congruent validity [59].
Implicit Association Test Self-Esteem (IAT) [60]. The
IAT will be used to assess implicit self-esteem. The IAT
is a computer-administered task, which measures the
automatic associations between concepts. The IAT is
based on a double discrimination task in which partici-
pants are asked to assign single stimuli as fast as possible
to a given pair of target categories. The internal
consistency has an average score of 0.70 [60].
Frost Multidimensional Perfectionism Scale (F-MPS)
[61]. We will use the F-MPS to assess perfectionism.
The scale contains 35 questions with a 5-point Likert
scale from “strongly disagree” to “strongly agree.” When
the scale was developed it measured six subscales of per-
fectionism. It is regarded as internally consistent, reliable
over time and displays sound concurrent validity [61,
62]. However, in practical applications, the six-factor
structure appeared to be unstable and an alternate four-
factor structure was proposed by several others [63, 64].
Inventory of Interpersonal Problems (IIP-32) [65]. The
IIP is a self-report questionnaire that measures the inter-
personal problems that people experience. The instru-
ment was first developed as a 127-item questionnaire on
the basis of a list of common interpersonal difficulties
raised by persons seeking psychotherapy. The 64-item
version was created by Alden et al. [66] specifically to pro-
vide a circumplex measure (originally called the IIP-C).
For this research we will use the shorter 32-item version
(IIP-32), which was developed with the aim of providing a
more rapid assessment with a good reliability and validity
[67]. All items are rated on a 5-point Likert scale ranging
from 0 (“not at all”) to 4 (“extremely”). The questionnaire
has good internal consistency, the coefficient alpha for the
scales of the IIP-32 are above 0.70 [65].
Sample size
In order to detect an absolute difference in recovery rate
from ED of 25% (CBT-E: 50% versus TAU: 25%), a
sample size of 66 patients per treatment condition is
required to provide 80% power at two-sided p < 0.05
(intention-to-treat analysis). This means that at least 132
patients are needed for this study.
Randomization, treatment allocation and blinding
Randomization takes place after screening of the inclu-
sion/exclusion criteria and signing of informed consent.
The research assistant will randomly assign the partici-
pating patients to CBT-E or TAU, stratified by center
and type of ED (AN, BN, BED, OSFED). Within each of
the twelve strata, a research assistant will randomize
participants using a permuted block design. Given the
nature of the psychological treatment neither the thera-
pists nor participants can be blinded for the delivered
treatment.
Data management and storage
All study-related data and other study material will be
stored securely at the study site (PsyQ The Hague).
Participant information and study data will be kept in
locked cabinets in areas with limited public access. After
obtaining informed consent, participants will be allo-
cated a unique code. The file that links participants to
their codes is stored on a secure server hosted by PsyQ
and is only accessible by the researcher and research
assistant. Any study material concerning participant in-
formation will not be released outside the study without
written permission from the participant. Online ques-
tionnaires will be collected using an authorized Survey-
Monkey account and downloaded and added to the
database. The SurveyMonkey security and privacy
statements for Internet security and handling personal
information and data can be found at, respectively, https://
www.surveymonkey.com/mp/policy/security/ and https://
www.surveymonkey.com/mp/policy/privacy-policy/.
Data collected on paper (SCID-I), will be manually en-
tered into a database. Data collected by the IAT computer
task will be transcripted and added to the database. Data
integrity will be enforced through several ways, including
valid values, range checks and consistency checks. The
master database will be held on a secure server hosted by
PsyQ, only accessible for authorized personnel involved in
the trial. All obtained data and administrative forms (e.g.,
informed consent) will be stored in accordance with the
data storage protocol for 15 years.
Statistical analysis
All participants who are randomized will be included in
the comparison and analyzed according to their random-
ized allocation (intent-to-treat analysis). Wherever pos-
sible, we will continue to collect follow-up data from
participants after any dropout from treatment or from the
study in order to keep the dataset as complete as possible.
In addition, baseline differences in study completers and
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dropouts will be analyzed with t tests for independent
samples or chi-square analyses if appropriate. Moreover,
we will perform a per-protocol analysis by including only
those participants who completed at least 70% of the
scheduled therapy sessions. All analyses will be carried out
using SPSS 23 [68].
Primary study parameter(s)
To test the hypothesis that CBT-E is more effective than
TAU, post-treatment differences in recovery rate (based
on SCID-I diagnosis) between conditions will be ana-
lyzed with chi-square analysis. Using logistic regression
analysis with recovery at post treatment as outcome and
treatment condition and baseline EDE-Q scores as pre-
dictors, whether differences in recovery rate between
conditions are independent of severity of ED pathology
at pre treatment will also be investigated. Moreover, the
course of scores from pre, mid and post treatment to
follow-ups I and II on the EDE-Q will be analyzed with
multilevel analysis (MLA). MLA is especially suitable to
analyze repeated measures data because it takes into
account the dependencies among observations nested
within individuals. Another advantage of this method-
ology is its ability to handle missing data, a problem
often occurring in longitudinal research [69]. The data
have a three-level hierarchical (multilevel) structure: re-
peated measures at the first level, individuals at the sec-
ond level and treatment at the third level. Besides main
effects for treatment and time, whether groups differ in
their course of EDE-Q scores will be investigated by in-
cluding a treatment × time interaction term. Differences
between treatment centers will be investigated likewise.
Secondary study parameter(s); indirect clinical effectiveness
Three-level MLA will also be used to study the relative
efficacy of CBT-E versus TAU in reducing scores on the
secondary outcome measures.
Putative mediators
To test the hypothesis that the effects of the CBT-E/
TAU on the EDE-Q scores are mediated by the putative
mediators investigated (i.e., self-esteem, perfectionism
and interpersonal problems), first, standardized residua-
lized gain scores are calculated by removing the portion
of mid-treatment scores on the mediators that can be
predicted linearly by corresponding pre-treatment scores
and the portion of post-treatment EDE-Q scores that
can be predicted linearly by mid-treatment EDE-Q
scores. Next, following the analytic steps outlined by
Baron and Kenny [70] and Kraemer et al. [71] we will
test the significance of the following paths using linear re-
gression analyses: path a: the independent variable (i.e.,
CBT-E/TAU) must affect the mediator (i.e., pre- to mid-
residualized change scores for self-esteem, perfectionism
or interpersonal problems); path b: the mediator must
affect the dependent variable (i.e., mid- to post-
residualized EDE-Q change scores); path c: the independ-
ent variable must affect the dependent variable; and path
c’: the direct effects of treatment on the dependent
variable must be meaningfully reduced when including a
hypothesized mediator in the model. When early process
changes predict later outcome changes, it will be further
tested whether this prediction remains significant also
after controlling for autocorrelations (i.e., the correlations
between early and late process changes) and synchronous
correlations (i.e., the correlations between early process
and early outcome changes) [72]. The significance of the
indirect effect of treatment on EDE-Q scores through the
putative mediators will be determined using a bootstrap
approximation with 5000 iterations to obtain biased-
controlled confidence intervals. In case of multiple
significant mediators, the independent contribution of
these mediators will be further explored using mul-
tiple mediation models.
Cost-effectiveness analysis
We will apply a cost-utility analysis (CUA). The results
will be expressed as cost per Quality-adjusted Life Year
(QALY). The economic evaluation will be undertaken
from a societal perspective. Hence, all relevant effects
and costs due to resource utilization within and outside
the health care (direct costs) and costs due to produc-
tion losses (indirect costs) will be included. To examine
the cost-effectiveness of CBT-E compared to TAU the
EQ-5D, the SF-36 and the TiC-P will be used.
The cost utility will be calculated as an incremental
cost-effectiveness ratio (ICER) which is the ratio between
the difference in costs and the difference in QALYs. The
budget impact analysis (BIA) will be conducted from a
health care payer perspective according to the ISPOR
guidelines [57]. So, we will compare total health care
costs when applying the intervention compared to the
standard treatment for the target population in The
Netherlands. Cost-effectiveness analyses will be performed
using the ICEinfer package [73] within the R environ-
ment [74].
Dissemination
Results of the study will be presented at international
scientific congresses and published in international
scientific journals. Also, if applicable, the practical impli-
cations of the study outcome will be published in profes-
sional journals and can provide input for the Dutch
Multidisciplinary Guideline for the Treatment of Eating
Disorders. Moreover, depending on the outcome of the
study, research findings will be used in the training of
professionals.
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Ethical considerations
Ethical approval has been obtained from the Ethical
Review Board of the Leiden University Medical Center.
The Board of Directors at PsyQ agreed to support the
execution of the study. The Boards of Directors of the
three psychiatric regional centers that take part in the
study also gave their consent. All participants will be
extensively informed about the study, addressing confi-
dentiality and the right to abort their participation at
any time and without clarification; quitting the research
program will by no means affect the subsequent course
of treatment. No harm is expected from the interven-
tion. In case of clinical deterioration (for any reason),
the responsible clinical psychologist/psychiatrist can ad-
vise discontinuation of trial participation at any time.
Written information will be given. When the patient is
willing to continue, written consent is required. An inde-
pendent physician is appointed, to whom subjects can
address questions about the research before, during and
after a study. The independent physician is not involved
in the study itself.
Discussion
In this study we assess the effectiveness of CBT-E. In
addition to the assessment of changes in ED pathology
and comorbid other psychopathology, we will also assess
the differential cost-effectiveness of CBT-E compared to
that of TAU. This is an important strength of this study
because to our knowledge this has not yet been done. In
a time were resources in health care are limited this
question becomes more and more important. If CBT-E
appears to be cost-effective for a broad range of ED
patients, it would give the opportunity to offer treatment
for a severe mental disorder with fewer resources,
thereby increase the accessibility of specialized care for
patients with an ED.
A large sample will be recruited and the sample is a
clinically relevant one as it will be recruited among
consecutive patients from three outpatient centers and
few exclusion criteria are applied.
The follow-up will take place until 60 weeks after the
end of treatment which gives the opportunity to look for
long-term results. This is an important strength because
there are few effectiveness studies in the field of EDs
with long-term follow-up.
Low self-esteem, dysfunctional perfectionism and
interpersonal problems have been identified in clinical
practice and in research as possible factors for obstruc-
tion to change and progress. Therefore, these three
factors are measured during this RCT before, during and
after treatment to explore their possible predictive and/
or mediating effects on treatment outcome.
There are, however, also some limitations to consider
given the chosen research design.
Firstly, most of the measurements are conducted
online which reduces research costs and maximizes the
accessibility of participation. However, this could be a
limitation because of the nonstandardized assessment
situation and possible delay in collection of data between
the moment the questionnaires are sent and the moment
of completion.
Secondly, we include participants according to DSM-5
criteria while at the same time we use the SCID-I which
is validated to assess the presence of an ED according to
the DSM-IV. Because the SCID-I only covers AN, BN,
and EDNOS-BED, skip rules were changed or omitted
and parts of the Eating Disorder Examination (EDE)
[31] were added in order to diagnose DSM-5 AN, BN,
BED and OSFED. Although these adjustments have also
been used in a recent epidemiological study [32], they
have not yet been validated.
Thirdly, the present study uses TAU as the control
condition; no alternative control conditions such as a no-
treatment, waiting-list or placebo condition are included.
This could also be a limitation especially when we do not
find a difference in outcome between the two active treat-
ment conditions. When no difference in outcome will be
found, it will be difficult to determine to what extent the
effect of treatment has to be ascribed to nonspecific
factors, the effect of testing or the passage of time.
Fourthly, we designed our RCT as a superiority trial
with enough statistical power to detect a difference in
outcome between treatments (if present) with a medium
effect size. However, it could be considered a limitation
of the study that the power analysis was only based on
detecting such difference in recovery rate because, with
the therefore necessary 132 participants, only medium
to large mediation effects can be tested with a power of
80% using bias-corrected bootstrapping procedures [75].
Fifthly, although we will determine treatment integrity,
therapist competence in delivering the experimental
intervention will not be assessed. However, because all
participating CBT-E therapists will have been trained in
CBT-E, and will have treated at least three ED patients
with CBT-E under supervision before entering the trial,
a sufficient level of competence may be assumed.
Finally, the sample size is too small to allow subgroup
analyses and consequently the possible differential effect-
iveness of CBT-E for AN, BN, and EDNOS-BED cannot
be assessed. Moreover, the changes in thresholds for AN
and BN in DSM-5, the addition of BED as a new official
diagnosis, and the redefinition of the remaining EDs
from the DSM-IV EDNOS category into two categories
complicate investigations of the differential effectiveness
of CBT-E for diagnostic subcategories.
Trial status
Recruiting.
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